Table 1.

Striatal dopamine and metabolite levels in control and LPS treated mice.

	DA	DOPAC	HVA	5-HIAA	5-HT
Day 5
PBS	100.0 ± 25.9	100.0 ± 18.7	100.0 ± 30.4	100.0 ± 26.2	100.0 ± 26.8
LPS	66.5 ± 13.6	50.5 ± 7.7*	68.9 ± 0.12	90.6 ± 4.0	81.6 ± 17.1
Day 19
PBS	100.0 ± 25.7	100.0 ± 23.1	100.0 ± 17.7	100.0 ± 19.2	100.0 ± 20.3
LPS	27.1 ± 16.7*	45.0 ± 8.5*	25.1 ± 0.14*	67.7 ± 10.2	79.0 ± 14.7
Day 36
PBS	100.0 ± 14.9	100.0 ± 5.3	100.0 ± 16.5	100.0 ± 5.8	100.0 ± 10.0
LPS	61.8 ± 16.2*	82.2 ± 12.9*	79.8 ± 0.25*	97.4 ± 7.8	85.1 ± 14.5

Monoamine levels were measured using HPLC-ECD. Specific loss of dopamine (DA) and metabolites DOPAC and homovanillic acid (HVA) is shown by 19 days, with some recovery at 36 days. No significant changes were observed for striatal serotonin (5-HT) or its metabolite, 5-hydroxy-indole acetic acid (5-HIAA). Data expressed as mean percent of control ± SEM for 4-5 mice/group.

^*p < 0.05 for effect of LPS. All statistical analysis was performed on raw data.